All Posts Tagged With: "AUXL"
(ACOR) Company News for August 2, 2011 – Corporate Summary
• Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion,...
(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero...
(LLY) Eli Lilly’s Axiron Testosterone Deficiency Drug Launched in the U.S.
Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement...
(LLY) Eli Lilly and Company Gets FDA Approval of Axiron
Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy...
(AUXL) Auxilium Pharmaceuticals Reports Narrower Loss
Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 35 cents. Higher revenues...
(AUXL) Auxilium Pharmaceuticals Reports Quarterly Loss That Narrows
Strong Testim sales helped Auxilium Pharmaceuticals, Inc. (AUXL) report a narrower-than-expected net loss of 18 cents per share in the first quarter of 2010, 13 cents below the Zacks Consensus Estimate and...
(LLY) Eli Lilly and Company Expands Men’s Health Range
Eli Lilly and Co. (LLY) recently entered into a deal with Australian company, Acrux, which should help strengthen Lilly’s men’s health portfolio. Lilly acquired exclusive worldwide rights to commercialize...
(AUXL) Auxilium Pharmaceuticals’ Xiaflex Awarded FDA Approval
Auxilium Pharmaceuticals, Inc. (AUXL) recently received a major boost when the U.S. Food and Drug Administration (FDA) granted approval to Xiaflex for the treatment of adult Dupuytren’s contracture...
(AUXL) Auxilium Pharmaceuticals and Pfizer Announces EU Review Process
Auxilium Pharmaceuticals, Inc. (AUXL) and Pfizer Inc. (PFE) recently announced that the review process of their Marketing Authorization...
(ENDP) Endo Pharmaceuticals Hits FDA Roadblock With Aveed
Endo Pharmaceuticals (ENDP) hit a roadblock related to the approval of Aveed. Recently, the company received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New...
(AUXL) Auxilium Pharma Awaiting FDA Decision
Auxilium Pharma (AUXL) is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major...
(ENDP) Endo Pharmaceuticals Buys US Rights to Fortesta
Endo Pharmaceuticals (ENDP) signed an agreement with UK-based ProStrakan Group Plc to acquire exclusive rights to commercialize Fortesta in the U.S., where the product is currently under Food and Drug Administration (FDA) review.
Fortesta...
(AUXL) Trading FDA Decisions with Calendar Spreads
Joe Kunkle, The Investment U Research Team
FDA approvals/rejections...
(PFE) Pharmaceuticals & Biotech – Zacks Analyst Interviews
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent,...
(PFE) Pharmaceuticals & Biotech – Industry Outlook
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent,...